Overview

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
All
Summary
This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a strain of Respiratory Syncytial Virus.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Healthy male or female

- Between 18 to 45 years old

- Body Mass Index of 18 to 33 kg/m2

Exclusion Criteria:

- Acute or chronic medical illness

- Positive for Human Immunodeficiency Virus, Hepatitis B or C

- Nose or nasopharynx abnormalities

- Abnormal lung function